Journal: Biodrugs

Article Title: SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

doi: 10.1007/s40259-021-00511-9

Figure Lengend Snippet: SARS-CoV-2 reactivity and neutralization titer of IVIG/SCIG final containers from November 2020 to June 2021. a Scatter plot for reactivity of 10% IVIG/SCIG final containers normalized to 10% Ig in commercial IgG ELISA. Each dot represents the mean result of 8 determinations per sample counted as one measurement. The month of production is plotted against ELISA signal intensity, which was normalized against the WHO International Standard and to 10% IgG (100 mg/mL). b Neutralization titer of 10% IVIG/SCIG as determined by microneutralization assay is depicted on the left y -axis in IU/mL. Each dot represents the mean of triplicate analysis, counting as one measurement. Neutralization over time was fitted (solid line) using non-linear fit ‘exponential growth equation’ on the median values under GraphPad Prism version 8.4.3 (686). The cumulative minimal serologically relevant exposure of the total US population is depicted as a dash-dotted line (right y -axis) in blue. The latter were obtained from CDC Covid Data Tracker . c Correlation analysis of ELISA ( x -axis) and microneutralization results ( y -axis). Correlation coefficient was calculated using two-tailed, Gaussian distributed values at 95% CI (Pearson) under GraphPad Prism version 8.4.3 (686). BAU binding antibody units, CI confidence interval, IVIG/SCIG intravenous or subcutaneous immunoglobulin

Article Snippet: Neutralization over time was fitted (solid line) using non-linear fit ‘exponential growth equation’ on the median values under GraphPad Prism version 8.4.3 (686).

Techniques: Neutralization, Enzyme-linked Immunosorbent Assay, Microneutralization Assay, Two Tailed Test, Binding Assay